Skip to main content
Evidence Snapshot

Mitogen-activated protein kinase 10

CHEMBL2637 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T17:54:21Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2637
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitogen-activated protein kinase 10 as ChEMBL target CHEMBL2637, mapped to UniProt P53779. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitogen-activated protein kinase 10
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2637
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P53779
Mitogen-activated protein kinase 10
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Mitogen-activated protein kinase 10 matters

As of 2026-09-13

Mitogen-activated protein kinase 10 is reviewed as Mitogen-activated protein kinase 10 (UniProt P53779); Mitogen-activated protein kinase 10 shows late clinical disease relevance led by hearing loss. 3 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 18 approved drugs, 3105 compounds, and 670 assays, with lead potency reaching pChEMBL 10.2.

Disease context
hearing loss

Mitogen-activated protein kinase 10 shows late clinical disease relevance led by hearing loss. 3 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 3 additional disease programs remain visible in the same card. Linked drugs include BRIMAPITIDE, C-TERMINAL ACID.

Start review with hearing loss because it currently carries late clinical support. Linked drugs include BRIMAPITIDE, C-TERMINAL ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 18 approved drugs, 3105 compounds, and 670 assays for this target. The dominant activity type is IC50. CHEMBL210618 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL210618 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
18 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Mitogen-activated protein kinase 10 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P53779, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why hearing loss is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3105
Total Compounds
670
Total Assays
18
Approved Drugs
IC50: 2039.0, KI: 178.0, KD: 528.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL210618
 10.2 IC50 —
No preferred name
CHEMBL4546504
 10.0 IC50 —
No preferred name
CHEMBL3220502
 9.8 IC50 —
No preferred name
CHEMBL3220499
 9.6 IC50 —
No preferred name
CHEMBL3220493
 9.6 IC50 —

Approved Drugs

Structure Compound First Approval
FEDRATINIB
CHEMBL1287853
 2019
GILTERITINIB
CHEMBL3301622
 2018
ABEMACICLIB
CHEMBL3301610
 2017
NINTEDANIB
CHEMBL502835
 2014
GEFITINIB
CHEMBL939
 2003
IMATINIB
CHEMBL941
 2001
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T17:54:21Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2637